Long-term immunological follow-up of children with haemophilus influenzae serotype b vaccine failure in the United Kingdom

Clinical Infectious Diseases

Volumn 49, Issue 3, 2009, Pages 372-380

  Ladhani, Shamez ^a,b   Heath, Paul T ^c   Ramsay, Mary E ^b   Slack, Mary P E ^b   Kibwana, Elizabeth ^d   Pollard, Andrew J ^d   Booy, Robert ^a,e  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b PUBLIC HEALTH ENGLAND   (United Kingdom)

^c ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^d UNIVERSITY OF OXFORD   (United Kingdom)

^e UNIVERSITY OF SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIUM ANTIBODY; HAEMOPHILUS INFLUENZAE TYPE B ANTIBODY; HAEMOPHILUS INFLUENZAE TYPE B VACCINE; UNCLASSIFIED DRUG;

ADOLESCENT; ANTIBODY BLOOD LEVEL; ARTICLE; BLOOD SAMPLING; CHILD; CONTROLLED STUDY; DOWN SYNDROME; FEMALE; FOLLOW UP; HAEMOPHILUS INFLUENZAE TYPE B; HUMAN; IMMUNOGLOBULIN DEFICIENCY; INFANT; INFECTION RISK; INFLUENZA; INFLUENZA VACCINATION; MAJOR CLINICAL STUDY; MALE; PREMATURITY; PRESCHOOL CHILD; PRIORITY JOURNAL; QUESTIONNAIRE; UNITED KINGDOM; VACCINE FAILURE;

ADOLESCENT; ANTIBODIES, BACTERIAL; BACTERIAL CAPSULES; CHILD; CHILD, PRESCHOOL; FEMALE; GREAT BRITAIN; HAEMOPHILUS INFECTIONS; HAEMOPHILUS INFLUENZAE; HAEMOPHILUS VACCINES; HUMANS; INFANT; MALE; VACCINES, CONJUGATE;

EID: 67651087009     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/600292     Document Type: Article

References (47)

1. Eskola J, Peltola H, Takala AK, et al. Efficacy of Haemophilus influenzae type b polysaccharide-diphtheria toxoid conjugate vaccine in infancy. N Engl J Med 1987; 317:717-22.
2. Booy R, Moxon ER, Macfarlane JA, Mayon-White RT, Slack MP. Efficacy of Haemophilus influenzae type B conjugate vaccine in Oxford region. Lancet 1992; 340:847.
3. Vadheim CM, Greenberg DP, Partridge S, Jing J, Ward JI. Effectiveness and safety of an Haemophilus influenzae type b conjugate vaccine (PRP- T) in young infants. Kaiser-UCLA Vaccine Study Group. Pediatrics 1993; 92:272-9.
4. Booy R, Hodgson S, Carpenter L, et al. Efficacy of Haemophilus influenzae type b conjugate vaccine PRP-T. Lancet 1994; 344:362-6.
5. Peltola H. Worldwide Haemophilus influenzae type b disease at the beginning of the 21st century: global analysis of the disease burden 25 years after the use of the polysaccharide vaccine and a decade after the advent of conjugates. Clin Microbiol Rev 2000; 13:302-17.
6. Ramsay ME, McVernon J, Andrews NJ, Heath PT, Slack MP. Estimating Haemophilus influenzae type b vaccine effectiveness in England and Wales by use of the screening method. J Infect Dis 2003; 188:481-5.
7. Heath PT, Booy R, Azzopardi HJ, et al. Antibody concentration and clinical protection after Hib conjugate vaccination in the United Kingdom. JAMA 2000; 284:2334-40.
8. Booy R, Taylor SA, Dobson SR, et al. Immunogenicity and safety of PRP-T conjugate vaccine given according to the British accelerated immunisation schedule. Arch Dis Child 1992; 67:475-8.
9. Begg NT, Miller E, Fairley CK, et al. Antibody responses and symptoms after DTP and either tetanus or diphtheria Haemophilus influenzae type B conjugate vaccines given for primary immunisation by separate or mixed injection. Vaccine 1995; 13:1547-50.
10. Heath PT, McVernon J. The UK Hib vaccine experience. Arch Dis Child 2002; 86:396-9.
11. Ladhani S, Slack MP, Heath PT, Ramsay ME. Changes in ascertainment of Hib and its influence on the estimation of disease incidence in the United Kingdom. Epidemiol Infect 2007; 135:861-7.
12. Ladhani S, Slack MP, Heys M, White J, Ramsay ME. Fall in Haemophilus influenzae serotype b (Hib) disease following implementation of a booster campaign. Arch Dis Child 2008; 93:665-9.
13. McVernon J, Andrews N, Slack MP, Ramsay ME. Risk ofvaccine failure after Haemophilus influenzae type b (Hib) combination vaccines with acellular pertussis. Lancet 2003; 361:1521-3.
14. Breukels MA, Spanjaard L, Sanders LA, Rijkers GT. Immunological characterization of conjugated Haemophilus influenzae type b vaccine failure in infants. Clin Infect Dis 2001; 32:1700-5.
15. Rijkers GT, Vermeer-de Bondt PE, Spanjaard L, Breukels MA, Sanders EA. Return of Haemophilus influenzae type b infections. Lancet 2003; 361:1563-4.
16. Heath PT, Booy R, Griffiths H, et al. Clinical and immunological risk factors associated with Haemophilus influenzae type b conjugate vaccine failure in childhood. Clin Infect Dis 2000; 31:973-80.
17. Lee YC, Kelly DF, Yu LM, et al. Haemophilus influenzae type b vaccine failure in children is associated with inadequate production of high-quality antibody. Clin Infect Dis 2008; 46:186-92.
18. Booy R, Heath PT, Slack MP, Begg N, Moxon ER. Vaccine failures after primary immunisation with Haemophilus influenzae type-b conjugate vaccine without booster. Lancet 1997; 349:1197-202.
19. Ladhani S, Heath PT, Aibara RJ, et al. Complications and risk ofserious infection following Haemophilus influenzae serotype b disease in vaccinated children. Arch Dis Child 2009; 93(Suppl 1):A80.
20. Cartwright KA, Begg NT, Rudd PT. Use of vaccines and antibiotic prophylaxis in contacts and cases of Haemophilus influenzae type b (Hib) disease. Commun Dis Rep CDR Rev 1994; 4:R16-7.
21. Trotter CL, McVernon J, Andrews NJ, Burrage M, Ramsay ME. Antibody to Haemophilus influenzae type b after routine and catch-up vaccination. Lancet 2003; 361:1523-4.
22. Phipps DC, West J, Eby R, Koster M, Madore DV, Quataert SA. An ELISA employing a Haemophilus influenzae type b oligosaccharide human serum albumin conjugate correlates with the radioantigen binding assay. J Immunol Methods 1990; 135:121-8.
23. Madore DV, Anderson P, Baxter BD, et al. Interlaboratory study evaluating quantitation of antibodies to Haemophilus influenzae type b polysaccharide by enzyme-linked immunosorbent assay. Clin Diagn Lab Immunol 1996; 3:84-8.
24. Milford Ward A, Sheldon J, Rowbotom A, Wild GD. PRU handbook of clinical immunochemistry. 9th ed. Sheffield, United Kingdom: PRU Publications, 2007.
25. Statutory Instrument 2002. No. 1438. The Health service (Control of Patient Information) Regulations 2002. http://www.opsi.gov.uk/si/ si2002/20021438.htm. Accessed 17 June 2009.
26. Kayhty H, Peltola H, Karanko V, Makela PH. The protective level of serum antibodies to the capsular polysaccharide of Haemophilus influenzae type b. J Infect Dis 1983; 147:1100.
27. Kayhty H. Difficulties in establishing a serological correlate of protection after immunization with Haemophilus influenzae conjugate vaccines. Biologicals 1994; 22:397-402.
28. Fogarty J, Moloney AC, Newell JB. The epidemiology of Haemophilus influenzae type b disease in the Republic of Ireland. Epidemiol Infect 1995; 114:451-63.
29. Feldman S, Gigliotti F, Shenep JL, Roberson PK, Lott L. Risk of Haemophilus influenzae type b disease in children with cancer and response of immunocompromised leukemic children to a conjugate vaccine. J Infect Dis 1990; 161: 926-931.
30. Costa-Carvalho BT, Martinez RM, Dias AT, et al. Antibody response to pneumococcal capsular polysaccharide vaccine in Down syndrome patients. Braz J Med Biol Res 2006; 39:1587-92.
31. Avanzini MA, Soderstrom T, Wahl M, Plebani A, Burgio GR, Hanson LA. IgG subclass deficiency in patients with Down's syndrome and aberrant hepatitis B vaccine response. Scand J Immunol 1988;28: 465-70.
32. Vidor E, Hoffenbach A, Fletcher MA. Haemophilus influenzae type b vaccine: reconstitution of lyophilised PRP-T vaccine with a pertussis- containing paediatric combination vaccine, or a change in the primary series immunisation schedule, may modify the serum anti-PRP antibody responses. Curr Med Res Opin 2001; 17:197-209.
33. Eskola J, Ward J, Dagan R, Goldblatt D, Zepp F, Siegrist CA. Combined vaccination of Haemophilus influenzae type b conjugate and diphtheria-tetanus-pertussis containing acellular pertussis. Lancet 1999; 354:2063-8.
34. Daum RS, Zenko CE, Given GZ, Ballanco GA, Parikh H, Germino K. Magnitude of interference after diphtheria-tetanus toxoids-acellular pertussis/ Haemophilus influenzae type b capsular polysaccharide-tetanus vaccination is related to the number of doses administered. J Infect Dis 2001; 184:1293-9.
35. Johnson NG, Ruggeberg JU, Balfour GF, et al. Haemophilus influenzae type b reemergence after combination immunization. Emerg Infect Dis 2006; 12:937-41.
36. Haemophilus influenzae type b (Hib). In: Salisbury DM, Ramsay ME, Noakes K, eds. Immunisation against infectious disease. 3rd ed. London: Stationary Office, 2006:127-42.
37. Fothergill LD, Wright J. Influenzal meningitis: the relation of age incidence to the bactericidal power of blood against the causal organism. J Immunol 1933; 24:273-84.
38. AlexanderH,HeidlebergerM, LeidyG. Theprotectiveorcurativeelement in type B H. influenzae rabbit serum. Yonsei Med J 1944; 16:425.
39. Stieb DM, Frayha HH, Oxman AD, Shannon HS, Hutchison BG, Crombie FS. Effectiveness of Haemophilus influenzae type b vaccines. CMAJ 1990; 142:719-33.
40. Blanchard-Rohner G, Pollard AJ. Sustaining immunity after immunization against encapsulated bacteria. Hum Vaccin 2008; 4:309-12.
41. Kelly DF, Moxon ER, Yu LM, Pollard AJ. Haemophilus influenzae type b (Hib) anti-PRP antibody concentration and avidity index in 3-5 year old children since start of infant Hib immunisation in the UK. Clin Vaccine Immunol 2009; 16:246-52.
42. McVernon J, Trotter CL, Slack MP, Ramsay ME. Trends in Haemophilus influenzae type b infections in adults in England and Wales: surveillance study. BMJ 2004; 329:655-8.
43. McVernon J, Howard AJ, Slack MP, Ramsay ME. Long-term impact of vaccination on Haemophilus influenzae type b (Hib) carriage in the United Kingdom. Epidemiol Infect 2004; 132:765-7.
44. Heath PT, Bowen-Morris J, Griffiths D, Griffiths H, Crook DW, Moxon ER. Antibody persistence and Haemophilus influenzae type b carriage after infant immunisation with PRP-T. Arch Dis Child 1997; 77:488-92.
45. Oh SY, Griffiths D, John T, Lee YC, Yu LM, McCarthy N et al. School- aged children: a reservoir for continued circulation of Haemophilus influenzae type b in the United Kingdom. J Infect Dis 2008; 197:1275-81.
46. Booy R, Hodgson SA, Slack MP, Anderson EC, Mayon-White RT, Moxon ER. Invasive Haemophilus influenzae type b disease in the Oxford region (1985-91). Arch Dis Child 1993;69:225-8.
47. Chief Medical Officer. Haemophilus influenzae type b (Hib) vaccine for young children-catch-up campaign. 2007. Available at: http://www.dh.gov.uk/en/Publicationsandstatistics/Lettersandcirculars/ Professional letters/Chiefnursingofficerletters/DH-076965. Accessed 17 June 2009.